LONDON (Reuters) - AstraZeneca said on Monday its MedImmune biotech unit had struck a deal with unlisted U.S. company Omnis Pharmaceuticals on the development of cancer-fighting oncolytic viruses. The agreement will allow MedImmune to combine its experimental immunotherapy drugs with Omnis’ virus program, which is currently in initial Phase I clinical testing. Financial terms were not disclosed. Oncolytic viruses are designed to target tumor cells with the killing potency of viruses. (Reporting by Ben Hirschler, editing by Louise Heavens) via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment